Emory performs first robotic PAE and Y-90 mapping using Microbot's LIBERTY System

Microbot Medical Inc.

World's first robotic prostate artery embolization (PAE) for BPH performed with LIBERTY at Emory.
First robotic Y-90 radioembolization mapping for liver cancer completed using the same system.
LIBERTY is FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
Limited Market Release started November 2025; Full Market Release planned for April 2026 at SIR conference.
BPH affects approximately 40 million men in the U.S.; LIBERTY aims to become standard of care for PAE.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.